Teacher Retirement System of Texas Cuts Stake in Omnicell, Inc. (NASDAQ:OMCL)

Teacher Retirement System of Texas cut its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 47.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,901 shares of the company's stock after selling 12,781 shares during the period. Teacher Retirement System of Texas' holdings in Omnicell were worth $486,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Lazard Asset Management LLC grew its stake in Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after acquiring an additional 737,536 shares in the last quarter. Toronto Dominion Bank purchased a new position in Omnicell during the fourth quarter valued at $30,637,000. Dimensional Fund Advisors LP grew its stake in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Oberweis Asset Management Inc. purchased a new position in Omnicell during the fourth quarter valued at $14,834,000. Finally, Renaissance Technologies LLC grew its stake in Omnicell by 79.3% during the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock valued at $20,316,000 after acquiring an additional 201,831 shares in the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating for the company in a research note on Thursday, March 20th. Piper Sandler reissued an "overweight" rating on shares of Omnicell in a research note on Friday, May 23rd. Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Saturday, July 12th. Bank of America lifted their price objective on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research note on Friday, May 23rd. Finally, Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $44.83.

Omnicell Stock Performance

NASDAQ OMCL traded up $0.19 during mid-day trading on Thursday, reaching $27.97. 509,288 shares of the stock were exchanged, compared to its average volume of 562,197. The business's 50 day moving average is $29.02 and its 200-day moving average is $34.41. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.75. The company has a market capitalization of $1.31 billion, a P/E ratio of 60.81, a P/E/G ratio of 8.17 and a beta of 0.76. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.23 and a current ratio of 1.38.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.10. The business had revenue of $269.67 million for the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a net margin of 1.87% and a return on equity of 4.60%. The company's revenue was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. On average, equities research analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.